Zacks Investment Research on MSN5d
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 ApprovalDexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...
Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...
Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...
Zacks Investment Research on MSN1d
DXCM Inks Deal With Nanowear to Boost CGM Application Beyond DiabetesDexCom DXCM recently signed a licensing and data partnership with a privately held healthcare-at-home digital diagnostics company — Nanowear. Per the terms of the agreement, Nanowear will use glucose ...
"We conclude that the Dexcom 15-day G7 CGM is accurate and safe for use up to 15.5 days in adults with diabetes with a 27-minute warm-up," stated the investigators.
Dexcom (Nadsaq:DXCM) announced today that it launched a new multi-region report evaluating type 2 diabetes treatments.
DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025.
Jake Leach caught up with MedTech Dive during the ATTD conference to discuss new data on the company’s glucose monitors and ...
7h
Eligible residents living with diabetes in Saskatchewan who rely on any type of insulin may be eligible to receive coverage ...
The Joseph P. Addabbo Family Health Center (JPAFHC) in Southeast Queens is making significant strides in diabetes care in New ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback